Additionally, we evaluated the improved anti-relapsed B-ALL activity of CD22-targeted and dual-target CD19/CD22 CAR-T cells, but were unable to eradicate relapses. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.